Outcomes of Vdpace for Relapsed/Refractory Multiple Myeloma in the Era of Daratumumab Based Therapy

被引：0
|
作者：
Venkatesh, Priyanka [1 ,2 ]
Khasawneh, Ghena [1 ,3 ]
Hashmi, Hamza [1 ,4 ]
Alkharabsheh, Omar [1 ,5 ]
Paul, Barry [1 ,6 ]
Skikne, Barry S. [1 ,7 ]
Mahmoudjafari, Zahra [1 ,7 ]
Ahmed, Nausheen [1 ,7 ]
Abdallah, Al-Ola [1 ,7 ]
Atrash, Shebli [1 ,6 ]
机构：
[1] US Myeloma Innovat Res Collaborat USMIRC, Kansas City, KS USA
[2] Univ Kansas, Internal Med, Med Ctr, Kansas City, KS USA
[3] Jordan Univ Sci & Technol, Irbid, Jordan
[4] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC USA
[5] Univ S Alabama, Mobile, AL USA
[6] Atrium Hlth, Levine Canc Inst, Plasma Cell Disorders Sect, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA
[7] Univ Kansas, Div Hematol Malignancies & Cellular Therapeut, Med Ctr, Westwood, KS USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-188117
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).
    Gasparetto, Cristina
    Lentzsch, Suzanne
    Schiller, Gary J.
    Callander, Natalie Scott
    Tuchman, Sascha
    Bahlis, Nizar J.
    White, Darrell
    Chen, Christine
    Baljevic, Muhamed
    Sutherland, Heather J.
    Kotb, Rami
    Sebag, Michael
    LeBlanc, Richard
    Venner, Christopher P.
    Bensinger, William
    Rossi, Adriana C.
    Sheehan, Heidi
    Arazy, Melina
    Kai, Kazuharu
    Lipe, Brea
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] Weekly Carfilzomib Combined with Daratumumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
    Xu, Jiadai
    Liu, Peng
    BLOOD, 2024, 144 : 7052 - 7053
  • [43] Therapy of relapsed and relapsed-refractory Multiple Myeloma
    Driessen, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 8 - 8
  • [44] Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
    Dubey, A. P.
    Khatri, Sameer
    Maggo, Sachin
    Singh, Nilabh K.
    Sharma, Durgesh
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2020, 41 (06) : 846 - 849
  • [45] Daratumumab for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Center Experience
    Jimenez-Zepeda, Victor
    Duggan, Peter
    Neri, Paola
    Luider, Joanne
    Tay, Jason
    Bahlis, Nizar J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E67 - E68
  • [46] Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.
    Plesner, Torben
    Arkenau, Hendrik-Tobias
    Lokhorst, Henk M.
    Gimsing, Peter
    Krejcik, Jakub
    Lemech, Charlotte Rose
    Minnema, Monique
    Lassen, Ulrik Niels
    Ahmadi, Tahamtan
    Yeh, Howard
    Guckert, Mary
    Brun, Nikolai C.
    Lisby, Steen
    Basse, Linda
    Palumbo, Antonio
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma
    Hirohiko Shibayama
    Morio Matsumoto
    Hiroshi Kosugi
    Kazuhiro Shibayama
    Hiroshi Yamazaki
    Shinsuke Iida
    International Journal of Hematology, 2021, 113 : 112 - 121
  • [48] Lighthouse: melflufen, daratumumab, and dexamethasone versus daratumumab in relapsed/refractory multiple myeloma refractory to an imid and a proteasome inhibitor or with ≥3 prior lines of therapy
    Mateos, Maria-Victoria
    Szarejko, Monika
    Bila, Jelena
    Schjesvold, Fredrik
    Spicka, Ivan
    Maisnar, Vladimir
    Jurczyszyn, Artur
    Grudeva-Popova, Zhanet
    Hajek, Roman
    Usenko, Hanna
    Thuresson, Marcus
    Norin, Stefan
    Jarefors, Sara
    Richardson, Paul
    Pour, Ludek
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S200 - S201
  • [49] Real-World Outcomes for the Treatment of Relapsed/Refractory Multiple Myeloma With Daratumumab: A Systematic Literature Review
    Gros Otero, B.
    Gungor, G.
    Gruppe, T. L.
    Wan, M.
    Jenkins, C.
    Helme, K.
    VALUE IN HEALTH, 2022, 25 (12) : S494 - S494
  • [50] Subcutaneous treatment with daratumumab for relapsed or refractory myeloma
    Stocker, Nicolas
    HEMATOLOGIE, 2020, 26 (03): : 149 - 150
12345